Reply to: Organ donation after ECPR: ethical challenges and clinical implications

• by Sasa Rajsic, Eduard Argudo, Sylvia Maria Belda Hofheinz, María Martínez Martínez, Ana Delgado, Marta Velia Antonini, Jonah Rubin, Robert Breitkopf

• September 25, 2026

Geospatial Optimization of Trauma Care Resource Allocation and Timely Access for Severely Injured Patients

• by Ryan B. Choi, Deeksha Bidare, Byung Hee Kang, Junsik Kwon, Kyungwon Jung, Jeff Choi

• September 29, 2026

Tele-ICU for patients after cardiac surgery: experience from the TELESCOPE trial

• by Tarso Augusto Duenhas Accorsi, Renato Carneiro de Freitas Chaves, Carlos Henrique Sartorato Pedrotti, Danilo Teixeira Noritomi, Otavio Tavares Ranzani, Adriano José Pereira

• September 29, 2026

FDA clears targeted cholangiocarcinoma therapy

In the single-arm REFOCUS trial, 46% of patients responded to treatment, with a median response duration of 11.8 months.

• by Kathryn Wighton

• September 24, 2026

• 2 min